| 序号 | CAS | 产品名称 | 规格 | 包装 |
参考价格 |
| 1 | 1072833-77-2 | Ixazomib(MLN2238) |
≥98% | | 询价 |
| 2 | 903564-48-7 | UM-164 |
≥98% | | 询价 |
| 3 | 717907-75-0 | PF-562271 |
≥98% | | 询价 |
| 4 | 714272-27-2 | Plinabulin(NPI-2358) |
≥98% | | 询价 |
| 5 | 129497-78-5 | Verteporfin(DB-00460,CL-318952,BPD-MA,BpdMA) |
≥98% | | 询价 |
| 6 | 117570-53-3 | Vadimezan(DMXAA,NSC640488,ASA404) |
≥98% | | 询价 |
| 7 | 856243-80-6 | Degrasyn(WP-1130) |
≥98% | | 询价 |
| 8 | 859212-16-1 | Bafetinib(INNO-406 NS187) |
≥98% | | 询价 |
| 9 | 778270-11-4 | GNF-2 |
≥98% | | 询价 |
| 10 | 1020172-07-9 | Rebastinib(DCC2036) |
≥98% | | 询价 |
| 11 | 260415-63-2 | PD173955 |
≥98% | | 询价 |
| 12 | 1421783-64-3 | Olverembatinib Dimesylate(GZD824) |
≥98% | | 询价 |
| 13 | 778277-15-9 | GNF-5 |
≥98% | | 询价 |
| 14 | 926037-48-1 | Radotinib(IY 5511 Supect) |
≥98% | | 询价 |
| 15 | 839706-07-9 | GNF-7 |
≥98% | | 询价 |
| 16 | 1360460-82-7 | Anlotinib Dihydrochloride |
≥98% | | 询价 |
| 17 | 641571-10-0 | Nilotinib(AMN107 Tasigna) |
≥98% | | 询价 |
| 18 | 837422-57-8 | WH-4-023 |
≥98% | | 询价 |
| 19 | 330161-87-0 | SU6656 |
≥98% | | 询价 |
| 20 | 172889-26-8 | PP1 |
≥98% | | 询价 |
| 21 | 172889-27-9 | PP2(AG1879) |
≥98% | | 询价 |
| 22 | 897016-82-9 | Tirbanibulin(KX2391 KX-O1) |
≥98% | | 询价 |
| 23 | 380843-75-4 | Bosutinib(SKI-606 Bosulif) |
≥98% | | 询价 |
| 24 | 379231-04-6 | Saracatinib(AZD0530) |
≥98% | | 询价 |
| 25 | 1073154-85-4 | Defactinib(VS6063,PF04554878) |
≥98% | | 询价 |
| 26 | 1061353-68-1 | PND-1186(VS-4718 SR-2156) |
≥98% | | 询价 |
| 27 | 717906-29-1 | PF-431396 |
≥98% | | 询价 |
| 28 | 846557-71-9 | ML385 |
| 5mg, 10mg, 25mg | 询价 |
| 29 | 939791-41-0 | PF-562271 HCl |
≥98% | | 询价 |
| 30 | 761437-28-9 | TAE226(NVP-TAE226) |
≥98% | | 询价 |
| 31 | 869288-64-2 | PF-573228 |
≥98% | | 询价 |
| 32 | 1025687-58-4 | Fostamatinib Disodium(R788 Tavalisse) |
≥98% | | 询价 |
| 33 | 939791-38-5 | PF-00562271 Besylate |
≥98% | | 询价 |
| 34 | 1229208-44-9 | Entospletinib(GS9973) |
≥98% | | 询价 |
| 35 | 10083-24-6 | Piceatannol(Astringenin NSC-622471 trans-Piceatannol) |
≥98% | | 询价 |
| 36 | 901119-35-5 | Fostamatinib(R788 Tavalisse) |
≥98% | | 询价 |
| 37 | 1370261-97-4 | PRT062607(P505-15,BIIB057)HCl |
≥98% | | 询价 |
| 38 | 841290-80-0 | Tamatinib(R-406) |
≥98% | | 询价 |
| 39 | 1351635-67-0 | ONO-4059 analogue |
≥98% | | 询价 |
| 40 | 1242156-23-5 | RN486 |
≥98% | | 询价 |
| 41 | 332013-26-0 | Telatinib mesylate(Bay 57-9352 mesylate) |
≥98% | | 询价 |
| 42 | 1708971-55-4 | Roblitinib(FGF 401) |
≥98% | | 询价 |
| 43 | 183321-74-6 | Erlotinib(OSI744,Tarceva) |
≥98% | | 询价 |
| 44 | 194423-06-8 | CL-387785(EKI-785) |
≥98% | | 询价 |
| 45 | 850140-73-7 | Afatinib(BIBW2992)Dimaleate |
≥98% | | 询价 |
| 46 | 1421373-98-9 | AZ5104 |
≥98% | | 询价 |
| 47 | 231277-92-2 | Lapatinib(GW-572016,Tykerb,Tyverb) |
≥98% | | 询价 |
| 48 | 267243-28-7 | Canertinib(CI-1033 PD-183805) |
≥98% | | 询价 |
| 49 | 1626387-80-1 | Zorifertinib(AZD3759 AZD-3759 zorifertinibum) |
≥98% | | 询价 |
| 50 | 698387-09-6 | Neratinib(HKI-272 PB272 Nerlynx) |
≥98% | | 询价 |
| 51 | 850140-72-6 | Afatinib(BIBW2992) |
≥98% | | 询价 |
| 52 | 388082-77-7 | Lapatinib Ditosylate(GW-572016,Tykerb) |
≥98% | | 询价 |
| 53 | 184475-35-2 | Gefitinib(ZD 1839) |
≥98% | | 询价 |
| 54 | 183319-69-9 | Erlotinib HCl(OSI-744,Tarceva) |
≥98% | | 询价 |
| 55 | 33069-62-4 | Paclitaxel |
| 10mg, 50mg, 100mg | 询价 |
| 56 | 332012-40-5 | Telatinib(BAY 57-9352) |
≥98% | | 询价 |
| 57 | 187389-52-2 | Z-VAD-FMK |
| 1mg, 5mg, 10mg | 询价 |
| 58 | 857876-30-3 | Motesanib Diphosphate(AMG-706) |
≥98% | | 询价 |
| 59 | 656247-17-5 | Nintedanib(Vargatef BIBF 1120) |
≥98% | | 询价 |
| 60 | 763113-22-0 | AZD2281(Olaparib) |
| 10mg, 25mg, 50mg, 100mg | 询价 |
m.cnreagent.com